231 related articles for article (PubMed ID: 32646889)
21. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia.
Cayuela JM; Baruchel A; Orange C; Madani A; Auclerc MF; Daniel MT; Schaison G; Sigaux F
Blood; 1996 Jul; 88(1):302-8. PubMed ID: 8704188
[TBL] [Abstract][Full Text] [Related]
22. Germline PAX5 mutations and B cell leukemia.
Hyde RK; Liu PP
Nat Genet; 2013 Oct; 45(10):1104-5. PubMed ID: 24071841
[TBL] [Abstract][Full Text] [Related]
23. Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker.
Nasr MR; Rosenthal N; Syrbu S
Am J Clin Pathol; 2010 Jan; 133(1):41-8. PubMed ID: 20023257
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of PAX5 gene in the early stages of leukemic B cells in the childhood B cell acute lymphoblastic leukemia.
Firtina S; Sayitoglu M; Hatirnaz O; Erbilgin Y; Oztunc C; Cinar S; Yildiz I; Celkan T; Anak S; Unuvar A; Devecioglu O; Timur C; Aydogan G; Akcay A; Atay D; Turkkan E; Karaman S; Orhaner B; Sarper N; Deniz G; Ozbek U
Leuk Res; 2012 Jan; 36(1):87-92. PubMed ID: 21813177
[TBL] [Abstract][Full Text] [Related]
25. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
[TBL] [Abstract][Full Text] [Related]
26. PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120.
Fazio G; Bresolin S; Silvestri D; Quadri M; Saitta C; Vendramini E; Buldini B; Palmi C; Bardini M; Grioni A; Rigamonti S; Galbiati M; Mecca S; Savino AM; Peloso A; Tu JW; Bhatia S; Borkhardt A; Micalizzi C; Lo Nigro L; Locatelli F; Conter V; Rizzari C; Valsecchi MG; Te Kronnie G; Biondi A; Cazzaniga G
EBioMedicine; 2022 Sep; 83():104224. PubMed ID: 35985167
[TBL] [Abstract][Full Text] [Related]
27. Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.
Li J; Dai Y; Wu L; Zhang M; Ouyang W; Huang J; Chen S
Front Med; 2021 Jun; 15(3):347-371. PubMed ID: 33400146
[TBL] [Abstract][Full Text] [Related]
28. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods.
Dworzak MN; Stolz F; Fröschl G; Printz D; Henn T; Fischer S; Fleischer C; Haas OA; Fritsch G; Gadner H; Panzer-Grümayer ER
Exp Hematol; 1999 Apr; 27(4):673-81. PubMed ID: 10210325
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
DiGiuseppe JA; Fuller SG; Borowitz MJ
Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
[TBL] [Abstract][Full Text] [Related]
30. PAX5 P80R-mutated B-cell acute lymphoblastic leukemia with transformation to histiocytic sarcoma: clonal evolution assessment using NGS-based immunoglobulin clonality and mutation analysis.
Kroeze LI; Scheijen B; Hebeda KM; Rijntjes J; Luijks JACW; Evers D; Hobo W; Groenen PJTA; van den Brand M
Virchows Arch; 2023 Jul; 483(1):105-110. PubMed ID: 36241730
[TBL] [Abstract][Full Text] [Related]
31. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
Steeghs EMP; Boer JM; Hoogkamer AQ; Boeree A; de Haas V; de Groot-Kruseman HA; Horstmann MA; Escherich G; Pieters R; den Boer ML
Sci Rep; 2019 Mar; 9(1):4634. PubMed ID: 30874617
[TBL] [Abstract][Full Text] [Related]
32. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
[TBL] [Abstract][Full Text] [Related]
33. PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-lineage acute lymphoblastic leukemia.
Kim M; Choi JE; She CJ; Hwang SM; Shin HY; Ahn HS; Yoon SS; Kim BK; Park MH; Lee DS
Blood Cells Mol Dis; 2011 Jun; 47(1):62-6. PubMed ID: 21549623
[TBL] [Abstract][Full Text] [Related]
34. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.
Hirabayashi S; Ohki K; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yaguchi A; Terada K; Saito Y; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fujimura J; Hino M; Kinoshita A; Kakuda H; Kurosawa H; Kato K; Kajiwara R; Moriwaki K; Morimoto T; Nakamura K; Noguchi Y; Osumi T; Sakashita K; Takita J; Yuza Y; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Fukushima T; Koh K; Manabe A; Ohara A; Kiyokawa N;
Haematologica; 2017 Jan; 102(1):118-129. PubMed ID: 27634205
[TBL] [Abstract][Full Text] [Related]
35. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.
Shah S; Schrader KA; Waanders E; Timms AE; Vijai J; Miething C; Wechsler J; Yang J; Hayes J; Klein RJ; Zhang J; Wei L; Wu G; Rusch M; Nagahawatte P; Ma J; Chen SC; Song G; Cheng J; Meyers P; Bhojwani D; Jhanwar S; Maslak P; Fleisher M; Littman J; Offit L; Rau-Murthy R; Fleischut MH; Corines M; Murali R; Gao X; Manschreck C; Kitzing T; Murty VV; Raimondi S; Kuiper RP; Simons A; Schiffman JD; Onel K; Plon SE; Wheeler D; Ritter D; Ziegler DS; Tucker K; Sutton R; Chenevix-Trench G; Li J; Huntsman DG; Hansford S; Senz J; Walsh T; Lee M; Hahn CN; Roberts K; King MC; Lo SM; Levine RL; Viale A; Socci ND; Nathanson KL; Scott HS; Daly M; Lipkin SM; Lowe SW; Downing JR; Altshuler D; Sandlund JT; Horwitz MS; Mullighan CG; Offit K
Nat Genet; 2013 Oct; 45(10):1226-1231. PubMed ID: 24013638
[TBL] [Abstract][Full Text] [Related]
36. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
[TBL] [Abstract][Full Text] [Related]
37. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.
Gu Z; Churchman ML; Roberts KG; Moore I; Zhou X; Nakitandwe J; Hagiwara K; Pelletier S; Gingras S; Berns H; Payne-Turner D; Hill A; Iacobucci I; Shi L; Pounds S; Cheng C; Pei D; Qu C; Newman S; Devidas M; Dai Y; Reshmi SC; Gastier-Foster J; Raetz EA; Borowitz MJ; Wood BL; Carroll WL; Zweidler-McKay PA; Rabin KR; Mattano LA; Maloney KW; Rambaldi A; Spinelli O; Radich JP; Minden MD; Rowe JM; Luger S; Litzow MR; Tallman MS; Racevskis J; Zhang Y; Bhatia R; Kohlschmidt J; Mrózek K; Bloomfield CD; Stock W; Kornblau S; Kantarjian HM; Konopleva M; Evans WE; Jeha S; Pui CH; Yang J; Paietta E; Downing JR; Relling MV; Zhang J; Loh ML; Hunger SP; Mullighan CG
Nat Genet; 2019 Feb; 51(2):296-307. PubMed ID: 30643249
[TBL] [Abstract][Full Text] [Related]
38. A novel class of ZNF384 aberrations in acute leukemia.
Zaliova M; Winkowska L; Stuchly J; Fiser K; Triska P; Zwyrtkova M; Hrusak O; Starkova J; Sramkova L; Stary J; Trka J; Zuna J
Blood Adv; 2021 Nov; 5(21):4393-4397. PubMed ID: 34529760
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.
Jeha S; Choi J; Roberts KG; Pei D; Coustan-Smith E; Inaba H; Rubnitz JE; Ribeiro RC; Gruber TA; Raimondi SC; Karol SE; Qu C; Brady SW; Gu Z; Yang JJ; Cheng C; Downing JR; Evans WE; Relling MV; Campana D; Mullighan CG; Pui CH
Blood Cancer Discov; 2021 Jul; 2(4):326-337. PubMed ID: 34250504
[TBL] [Abstract][Full Text] [Related]
40. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
